JaxBio develops AI-based chips that utilize machine learning algorithms to identify cancer-specific biomarkers in blood samples, enabling the early detection and monitoring of various cancer types and subtypes. Their technology provides a fast, cost-effective, and highly sensitive blood test that improves diagnosis and therapy response prediction, addressing the critical need for timely cancer management.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EAFounders
Product
Problem
Current cancer diagnostic methods often lack the sensitivity for early detection and can be expensive and time-consuming. This results in delayed diagnoses, hindering timely treatment and negatively impacting patient outcomes.
Solution
JaxBio is developing a blood test that leverages AI and machine learning to identify cancer-specific biomarkers. Their platform probes thousands of biomarkers circulating in the blood, enabling early detection, monitoring of disease status, and prediction of therapy response. The goal is to provide a fast, cost-effective, and highly sensitive method for cancer diagnosis and management. By detecting cancer at earlier stages, treatment can be administered sooner, potentially improving survival rates.
Target Audience
The primary target audience includes healthcare providers, oncologists, and diagnostic laboratories seeking improved methods for early cancer detection and monitoring.
Features
- AI-driven analysis of blood samples for cancer-specific biomarker identification
- High-throughput platform capable of probing thousands of biomarkers
- Machine learning algorithms to identify different cancer types and subtypes at various stages
- Intended to enable early detection of cancer
- Designed to monitor disease status
- Aims to predict response to therapy